Ro 08-2750
CAS No. 37854-59-4
Ro 08-2750( —— )
Catalog No. M26808 CAS No. 37854-59-4
Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 56 | Get Quote |
|
| 10MG | 87 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameRo 08-2750
-
NoteResearch use only, not for human use.
-
Brief DescriptionRo 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 μM.
-
DescriptionRo 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 μM. Ro 08-2750 is a selective MSI RNA-binding activity inhibitor, with an IC50 of 2.7 μM. Ro 08-2750 inhibits NGF binding to p75NTR selectively over TRKA.(In Vitro):Ro 08-2750 inhibits the survival of human AML lines and patient cells. Ro 08-2750 suppresses MSI2 RNA-binding and alters the MSI2 gene signature. Ro 08-2750 binds to the NGF dimer thereby probably inducing a change in its conformation such that NGF cannot bind to p75NTR anymore. Ro 08-2750 (5-10 μM; 8 hours) increases differentiation and apoptosis in myeloid leukemia cells. Ro 08-2750 (10 nM) fully rescues cells from undergoing NGF-induced SK-N-MC 103 cell death .(In Vivo):In a myeloid leukemia model in vivo, Ro 08-2750 (13.75 mg/kg; i.p.) suppresses leukemogenesis .
-
In VitroRo 08-2750 binds to the NGF dimer thereby probably inducing a change in its conformation such that NGF cannot bind to p75NTR anymore.Ro 08-2750 (10 nM) completely rescues cells from undergoing NGF-induced SK-N-MC 103 cells death.Ro 08-2750 (5-10 μM; 8?hours) increases differentiation and apoptosis in myeloid leukemia cells.Ro 08-2750 inhibits survival of human AML lines and patient cells.Ro 08-2750 inhibits MSI2 RNA-binding and alters MSI2 gene signature. Apoptosis Analysis Cell Line:MLL-AF9?+?BM cells Concentration:5?μM, 10?μM Incubation Time:8?hours Result:Increased apoptosis.
-
In VivoRo 08-2750 (13.75mg/kg; i.p.) inhibits leukemogenesis in a myeloid leukemia model in vivo. Animal Model:C57BL/6 wild type mice (10-12-weeks-old), MLL-AF9 murine leukemia model Dosage:13.75?mg/kg Administration:Intraperitoneal injection, at days 1, 4, 7, 10, and 13 (one day on, two days off drug)Result:Inhibited c-MYC levels and reduced disease burden.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorAhR| Androgen Receptor| Antifungal| Estrogen Receptor/ERR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number37854-59-4
-
Formula Weight270.248
-
Molecular FormulaC13H10N4O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 4 mg/mL (14.80 mM)
-
SMILESCc1cc2nc3c(nc(=O)[nH]c3=O)n(C)c2cc1C=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Liu J, et al. Whole transcriptome analysis of Penicillium digitatum strains treatmented with prochloraz reveals their drug-resistant mechanisms. BMC Genomics. 2015 Oct 24;16:855.
molnova catalog
related products
-
tris(dibenzylideneac...
tris(dibenzylideneacetone)dipalladium is a N-myristoyltransferase-1 (NMT-1) inhibitor.
-
PLH1215
PLH1215 is an effective AHR inhibitor that can be used to modulate, limit, or suppress the expression of AVIL (advillin). PLH1215 can be employed for the prevention and treatment of cancer.
-
Mal-PEG5-Boc
Mal-PEG5-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
Cart
sales@molnova.com